MET and melanoma: About 50% of patients with melanoma have BRAF mutations and 15–20% of NRAS mutations leading to the constitutive activation of the MAPK signaling pathway [2] and Chattopadhyay et al. suggested that decreased c-Met activity in melanoma cells could be a useful therapeutic strategy [81].